Tags
Animas, FDA, FDA Warning Letter, Food & Drug Administration, Huffington Post, Johnson, New Brunswick, West Chester Pennsylvania
Johnson & Johnson hit with FDA warning letter | MassDevice – Medical Device Industry News.
Johnson & Johnson hit with FDA warning letter
January 12, 2012 by MassDevice staff
More regulatory woes as Johnson & Johnson hit with a warning letter from the FDA regarding its insulin pumps.
Animas Corp.’s OneTouch Ping
insulin pump
The FDA issued a warning letter to medical device giant Johnson & Johnson (NYSE:JNJ) saying that the company could face penalties including fines and injunction for failing to report incidents where its OneTouch Ping and 2020 insulin pumps may have caused death or serious injury.
In an inspection of the West Chester, Pa.-based plant, the federal watchdog agency found that J&J’s Animas Corp. never reported on 1 complaint about series patient injury and delayed reporting 2 other incidents to the FDA.
The affected patients were hospitalized with diabetic ketoacidosis – a complication caused when patients lack the insulin to break down blood sugar, high blood sugar, respiratory failure and coma, according to the letter.
The watchdog agency ordered the J&J subsidiary to explain, by Jan. 20, why it kept selling pumps known to fail. The company is also required to submit a plan to ensure that its failure to notify the FDA of devices that may cause serious injury or death in patients doesn’t have a repeat performance.
Animas spokeswoman Caroline Pavis told the Huffington Post that the company failed to report the 3 patient incidents to FDA because they involved patients that weren’t using the pumps as directed.
In 1 case, the patient ignored an alarm signaling that a cap had come off the machine, preventing insulin from being pumped into the body, Pavis told the new site.
Animas’ insulin pump problems are just the latest in a string of bad regulatory publicity for the New Brunswick, N.J. based medical device giant.
Just last week, the FDA ordered Johnson & Johnson, along with 32 other companies, to take another look at complication rates associated with their vaginal mesh products.
The watchdog agency asked a total of 33 companies to conduct 3 years of safety and effectiveness trials under growing concerns after deaths and injuries linked to the products spiked in recent years.
Subsidiary DePuy Orthopaedics could cost the med-tech titan up to $1 billion in lawsuits concerning metal-on-metal hip implants that were found to shed minute metal particles into a patient’s bloodstream over time.
Lawsuits over the ASR implant have piled up across the country, accusing DePuy of manufacturing a defective product, failing to warn patients and doctors of problems with the implant and negligence in designing, manufacturing and selling the product.
Related articles
- Johnson & Johnson Under Scrutiny By FDA For Delay In Reporting Insulin Pump Problems (huffingtonpost.com)
- FDA: J&J delayed reporting insulin pump problems (sfgate.com)
- FDA: J&J delayed reporting insulin pump problems (seattlepi.com)
- FDA: J&J delayed reporting insulin pump problems (usatoday.com)
- FDA: J&J delayed reporting insulin pump problems (seattletimes.nwsource.com)
- FDA: J&J waited to report insulin pump problems (msnbc.msn.com)
- FDA probes JNJ, Bard and others on transvaginal mesh risks | MassDevice – Medical Device Industry News (earlsview.com)
- FDA: J&J delayed reporting insulin pump problems (mysanantonio.com)
- Health equipment maker Midmark gets FDA warning letter on sterilizers (medcitynews.com)
- Sparta Systems Expert to Speak on Compliance and CAPA with AdvaMed at “Avoiding FDA Warning Letters” Panel (prweb.com)
This is a reflection of the incompetent way in which the FDA handles such matters, or maybe I should say the competent way the medical device world does handle the matter. For the life of me, if there is enough apparent problems with a medical device take it off the market, put it on the shelf and correct the problem.
This demonstrates the importance of Market Share, Finances and don’t forget the Investors, sell, sell, sell, so what if a few people get hurt.
The FDA sends a warning letter and then what do they do ? Send another warning letter or slap on the medical device manufacturers wrist, mean while innocent people are getting hurt. Is this justice or is this just another way for the FDA to demonstrate its weakness when dealing with the medical device world. This isn’t about the lack of funds to employ people to enforce the law, this is just another poor example of who is running the show, the medical device world.
Respectfully
Howard Sadwin
Absolutely right!
Earl
Pingback: FDA warns J&J’s DePuy unit over joint replacements – AlertNet « Earl's View
Pingback: Johnson & Johnson Takes $3 Billion Charge for Hip Recall – NYTimes.com « Earl's View
Pingback: Earl's View
Pingback: Consumer Reports taps ire over bad medical devices « Earl's View
Pingback: Gynecare Prolift Mesh Sold by J&J Without FDA Approval | InjuryBoard Fort Worth « Earl's View
Pingback: FDA Workers Say Outsiders Influence Medical Device Decisions | Patrick Malone & Associates P.C. | DC Injury Lawyers – JDSupra « Earl's View
Pingback: FDA Confirms Johnson & Johnson Prolift Pelvic Mesh Product Sold for Over 3 Years without Necessary FDA Clearance « Earl's View